Pfizer inks $2.6B licensing deal with Chinese biotech for CAR-T therapies
FROM THE WIRE · FINANCE.YAHOO.COM
Pfizer PFE announced that it has entered into an exclusive licensing deal with China-based Starna Therapeutics for the latter's three investigational chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases. Under the agreement, Starna Therapeutics will…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA $2.6 billion CAR-T licensing deal strengthens Pfizer's immunology pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Pfizer signed an exclusive license with Starna Therapeutics for three CAR-T programs.
- 02Starna will receive an upfront payment of $330 million.
- 03Pfizer will pay up to $2.3 billion in potential milestone payments.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets